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Porcine  enzootic  pneumonia  (PEP),  which  is caused  by  the  fastidious  bacterium  Mycoplasma  hyopneu-
moniae,  is  one  of the most  economically  important  diseases  in  the pig  industry  worldwide.  Commercial
bacterins  provide  only  partial  protection;  therefore,  the  development  of  more  efﬁcient  vaccines  against
PEP  is necessary.  In this  study,  the cellular  and  humoral  immune  responses  elicited  by  DNA  and  recombi-
nant  subunit  vaccines  based  on  the  P37,  P42,  P46  and  P95  antigens  of  M.  hyopneumoniae  were  evaluated




ellular  immune response
was  evaluated  by real-time  RT-PCR  in splenocytes  from  vaccinated  mice.  All  antigens  delivered  as  subunit
vaccines,  especially  P42  and P95,  and  the pcDNA3/P46  DNA  vaccine  were  able  to  elicit strong  immune
responses.  These  vaccines  induced  cellular  immune  responses  and the  production  of  antibodies  able  to
react  with  native  M. hyopneumoniae  proteins.  Because  both  cellular  and  humoral  immune  responses  were
induced,  P42  and  P95  are  promising  candidates  for a recombinant  subunit  vaccine  and  P46 is  a  promising
candidate  for  a  DNA  vaccine  against  PEP.. Introduction
Mycoplasma hyopneumoniae is the causative agent of porcine
nzootic pneumonia (PEP), a highly prevalent respiratory disease
hat causes major losses in pig farms worldwide. This disease is
haracterised by catarrhal pneumonia with chronic non-productive
ough, low feed conversion and delays in weight gain, leading to
igh morbidity and low mortality [1]. In addition, pigs with PEP are
redisposed to secondary infections [2].
PEP can be controlled with antibiotics and animal handling
rocedures. However, vaccination is considered the most efﬁcient
ontrol measure [3]. Commercially available vaccines consist of
nactivated whole-cell preparations and provide only partial pro-
ection [4,5]. Therefore, it is necessary to develop new alternative
accines. Some studies have reported that DNA vaccines favour
he Th1 immune response and thus promote a cellular immune
esponse [6–8]. Despite the fact that the mechanism of M.  hyop-
eumoniae pathogenesis has not been completely elucidated, it has
een suggested that a cell-mediated immune response is important
or disease control [5]. Thus, DNA vaccines represent a promising
trategy for developing more effective vaccines against PEP.
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After the sequencing and proteomic analysis of two  M.  hyopneu-
moniae strains [9], our research group produced and evaluated the
immunogenicity and antigenicity of 35 secreted recombinant pro-
teins [10–12] and six transmembrane recombinant proteins [13]
expressed in Escherichia coli. Some of these proteins were identi-
ﬁed as having the potential to be used as vaccine antigens, including
the molecular chaperone DnaK (P42 heat shock protein) and the
membrane surface protein P46. The latter has been tested as a DNA
vaccine but only as part of a cocktail, not individually [6,14]. Two
other recombinant proteins, P37-like ABC transporter substrate-
binding lipoprotein and the outer membrane protein P95, which
have not been evaluated previously, were also considered as poten-
tial antigens for use in subunit vaccines. None of these antigens have
been evaluated as DNA vaccines.
In this work, the cellular and humoral immune responses
elicited by the M. hyopneumoniae antigens P37, P42, P46 and P95,
delivered as DNA or recombinant subunit vaccines, were evaluated
in mice.
2.  Materials and methods
2.1.  Bacterial strains and plasmids
Open access under the Elsevier OA license.M. hyopneumoniae strain 7448 was  obtained from EMBRAPA
(Concórdia-SC, Brazil). E. coli TOP10 was used as a host strain for
cloning, and E. coli BL21(DE3)RIL was used as the expression strain.
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Table 1
M.  hyopneumoniae CDS selected and the respective primers and restriction enzymes used for cloning and site-directed mutation.
CDSa Features Primers Restriction enzymes
MHP0360 For P37 CGGGATCCGATCAAAAAGACTGGGAAAAATT BamHI
MHP0360  Forb P37 CGCGGGATCCAAAAAATGGACTGGGAAAAA BamHI
MHP0360  Rev P37  CGGAATTCTTAGTTAGATTCTGCATAAATCCG EcoRI
MHP0360  Revb P37 CGGAATTCTTAGTTAGATTCTGCATAAATCCG EcoRI
MHP0360  FM P37 CATTTGCTTGgACTGAAAGCAAA
MHP0360 RM P37 GCTTTCAGTcCAAGCAAATGAA
MHP0067 For P42 CACCATGGCGCTTACAAGACTTAA
MHP0067 Forb P42 CGCGGGATCCCAACGATGGTTTCAGCAAAAG BamHI
MHP0067  Rev P42 TGATTAATCCTGCTTGATTTCAGCAT
MHP0067  Revb P42 CCGGAATTCTTAATCCTGCTTGATTTCAGCA EcoRI
MHP0513  For P46 CACCCTCACTCAGCAAG
MHP0513 Forb P46 CGGGGTACCTCACTATGGAGCAAGCTAAT KpnI
MHP0513  Rev P46 TTAGGCATCAGGATTATCAACATTAGC
MHP0513 Revb P46 CGCGGATCCTTAGGCATCAGGATTATCAAC BamHI
MHP0513  FM P46 GTCCCAGGATGgAATTATGGAACT
MHP0513 RM P46  ATAATTcCATCCTGGGACATAAACAG
MHP0099 For P95 CACCAGCCGTCCTTTTTTTGAAA
MHP0099 Forb P95 CGCGGGATCCGAAGCATGGGTCCTTTTTTTG BamHI
MHP0099  Rev P95 TGATCAAAGTTTAAAAATCTCAGTTTCT
MHP0099 Revb P95 CCGGAATTCTCAAAGTTTAAAAATCTCAGTTTCTT EcoRI

































va NC 007332 GenBank® accession for M. hyopneumoniae strain 7448.
b Primers designed for cloning into pcDNA3.1 vector. The others were designed 
or  site-direct cloning into PET200D TOPO plasmid. Underlined nucleotides represe
he expression vectors Champion pET200D/TOPO and pcDNA3
ere purchased from Invitrogen, and the expression vector pAE
as obtained from Instituto Butantan [15].
.2. Ampliﬁcation of coding sequences and site-directed
utagenesis
The primers used were designed with VectorNTI 10 (Invitro-
en) software based on the genomic sequence of M. hyopneumoniae
train 7448 (GenBank accession NC 007332) (Table 1). The Kozak
equence was added to the forward primers to generate DNA
accines. The M.  hyopneumoniae P37, P42, P46 and P95 coding
equences were ampliﬁed and puriﬁed according to the method of
imionatto et al. [11]. MHP0246 (P37) and MHP0513 (P46), which
ontained a TGA codon in their nucleotide sequences, were sub-
ected to site-directed mutagenesis according to the method of
imionatto et al. [10], and the mutation was conﬁrmed by DNA
equencing using the Dye Terminator DYEnamic ET Cycle Sequenc-
ng kit and a MegaBACE 1000 DNA sequencer (GE Healthcare).
.3.  Recombinant subunit vaccine development
Recombinant proteins were expressed in E. coli BL21(DE3)RIL,
uriﬁed and quantiﬁed as described by Simionatto et al. [11].
ecombinant proteins were also characterised by Western blot-
ing using an anti-histidine tag monoclonal antibody conjugated to
eroxidase (Sigma Aldrich).
.4. In vitro transfection of Vero cells
DNA vaccines (pcDNA3/P37, pcDNA3/P42, pcDNA3/P46,
cDNA3/P95 and empty vector pcDNA3) were puriﬁed using the
ucleoBond® Xtra Maxi kit (Macherey Nagel), according to the
anufacturer’s instructions. These DNAs were used to transiently
ransfect Vero cells using LipofectamineTM 2000 (Invitrogen)
ccording to the manufacturer’s instructions. Immunoﬂuores-
ence analysis using mouse polyclonal serum previously produced
gainst recombinant proteins [12] and RT-PCR were performed to
onﬁrm the in vitro expression of the encoded antigens prior DNA
accination.ning into pAE or PET200D TOPO. Italic nucleotides represent CACC sequence used
 restriction site of the enzyme.
2.5. Inoculation of mice with the vaccine formulations
Female BALB/c mice aged 6–8 weeks (8 animals per group)
were immunised as follows: group 1, pcDNA3/P37; group 2,
pcDNA3/P42; group 3, pcDNA3/P46; group 4, pcDNA3/P95; group
5, P37; group 6, P42; group 7, P46, group 8, P95; group 9,
RespiSure® vaccine (Pﬁzer) (positive control); group 10, 100 l of
saline (negative control for subunit vaccines); and group 11, the
pcDNA3 vector (negative control for DNA vaccines). The recombi-
nant subunit vaccines and the saline were supplemented with 15%
aluminium hydroxide adjuvant. Two  doses of 50 g of protein or
DNA were administered intramuscularly (IM) separated by 21 days.
To enhance the uptake of the plasmid DNA by muscle cells, sucrose
(50 l of 25% solution) was  injected 30 min  before inoculation with
the DNA vaccines. Blood samples were collected from the retro-
orbital sinus at 0, 21, 42, 63 and 84 days after inoculation (DAI).
After the last blood sample was collected, the spleens of these ani-
mals were collected to evaluate cytokine production. During the
experiment, all animals were maintained in accordance with the
recommendations of the Brazilian College of Animal Experimenta-
tion and the Ethics Committee for Animal Experimentation of the
Federal University of Pelotas.
2.6.  Assessment of the humoral immune response
The humoral immune responses generated by immunisation
with recombinant proteins and DNA vaccines were assessed by
Western blotting and ELISA using recombinant proteins or crude
M. hyopneumoniae 7448 extract, as described by Simionatto et al.
[12]. An IgG anti-mouse antibody horseradish peroxidase conju-
gate (Sigma Aldrich) and antibodies supplied with the IsoQuickTM
kit (Sigma Aldrich) were used to evaluate the levels of IgG1 and
IgG2a antibodies. Sera from mice were assessed individually, and
all reactions were performed in triplicate. Sera from mice immu-
nised with saline or the commercial vaccine were used as negative
and positive controls, respectively.2.7.  Assessment of cytokine induction (INF , TNF  ˛ and IL1)
Total  RNA from splenocyte cultures was  extracted with the Tri-
zol Reagent® according to the manufacturer’s protocol. Then, cDNA
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Fig. 1. (A) Electrophoresis in a 0.8% agarose gel of the four recombinant plasmids
constructed  for use as DNA vaccines. Lane 1, pcDNA3/P37; Lane 2, pcDNA3/P42;


































Fig. 2. Optical density (mean ± SD) obtained for the indirect ELISA using serum
(diluted  1:50) from eight BALB/c mice immunised with the P37, P42, P46, P95,
pcDNA3/P37, pcDNA3/P42, pcDNA3/P46 and pcDNA3/P95 vaccines. Serum was  col-
lected on days 0, 21, 42, 63 and 84 DAI. An anti-mouse IgG-peroxidase conjugate
(diluted  1:4000) was used as the secondary antibody. The colorimetric reaction was
started by adding o-phenylenediamine dihydrochloride (Sigma Aldrich) and hydro-
gen peroxide and was stopped with 2 M H2SO4. The optical densities (492 nm) for
the subunit and DNA vaccines were subtracted from the optical density generatedAGE  of the four recombinant proteins puriﬁed by afﬁnity chromatography for use
s subunit vaccines. Lane 1, P37 (20 kDa); Lane 2, P42 (42 kDa); Lane 3, P46 (35 kDa);
nd Lane 4, P95 (41 kDa).
as synthesised and subjected to real-time PCR. The PCR condi-
ions used were as follows: a ﬁnal volume of 20 l containing 10 ng
f cDNA, 3.5 mM MgCl2, 3.1 pmol of primers, and 10 l of Platinum
ybr green UDG (Invitrogen). The ampliﬁcation was  standardised
n a 7500 Fast thermocycler (Applied Biosystems) using the fol-
owing temperature program: 50 ◦C for 20 s, 95 ◦C for 10 min  and
5 cycles of 15 s at 95 ◦C and 60 s at 60 ◦C. Melting curves were
btained using the following conditions: 15 s at 95 ◦C, 60 s at 60 ◦C,
0 s at 95 ◦C and 15 s at 60 ◦C. Primers to amplify cytokine genes
ere as previously described [16–18]. Primers were evaluated for
fﬁciency, which was close to 100%, allowing their use in real-time
CR assays. Graphs of the relative expression were generated using
he 2−Ct method [19].
.8. Statistical analysis
Signiﬁcant  differences in the ELISA results were identiﬁed by
nalysis of variance (ANOVA) using the Tukey test in SAS 9.1 [20].
 P value of 0.05 or 0.01 was considered signiﬁcant. Graphs were
repared in GraphPad Prism 5.
. Results
.1. Recombinant subunit and DNA vaccine development
All recombinant proteins (P37, P42, P46 and P95) were
xpressed in E. coli BL21(DE3)RIL and puriﬁed by afﬁnity chro-
atography with sufﬁcient purity and quantity for further studies
Fig. 1). The four selected targets were successfully ampliﬁed by
CR and cloned into pcDNA3. The obtained plasmids had high
urities (A260 > 1.8 and <2.2) and yields ranging from 500 to
500 g/L of culture (Fig. 1). The presence of speciﬁc mRNA was
eriﬁed by RT-PCR, and the expression of proteins was  assessed
y immunoﬂuorescence analysis of Vero cells transfected with the
ecombinant vectors..2.  Immunogenicity of recombinant subunit and DNA vaccines
The  total IgG antibody response induced by the recombinant
accines was determined after intramuscular (IM) immunisationby  the negative control (saline and pcDNA3, respectively). Small letters indicates
the  results of the ANOVA using the Tukey test, with P < 0.01 for day 84.
of BALB/c mice by indirect ELISA using recombinant proteins (Fig.
2). At 42 DAI, the sera of mice contained speciﬁc antibodies against
the recombinant P37, P42, P46 and P95 proteins, with a P value
<0.01 for the Tukey test relative to preimmune serum. This response
was constant until 84 DAI. The Serum of animals inoculated with
saline (negative control) and the commercial vaccine (positive
control) did not react with any recombinant proteins (data not
shown). Among the recombinant subunit vaccines tested, the P42
and P95 vaccines elicited the strongest immune responses (P < 0.01)
at 84 DAI. Among DNA vaccines, only the pcDNA3/P46 vaccine
induced seroconversion. The level of seroconversion induced by the
pcDNA3/P46 vaccine was  statistically equal to that induced by the
P95 recombinant subunit vaccine and was superior to that induced
by the P46 recombinant subunit vaccine (P < 0.01). Although the P42
and P95 vaccines showed a mixed IgG1/IgG2a immune response,
there was  a predominance of the humoral immune response (IgG1)
for all recombinant vaccines, even the pcDNA3/P46 vaccine (Fig. 3).
The P42 vaccine elicited the highest IgG1 and IgG2a levels, followed
by the P95 and pcDNA3/P46 vaccines.
The sera of mice immunised with the P42, P46, P95 and
pcDNA3/P46 vaccines (84 DAI) and the commercial vaccine (pos-
itive control) signiﬁcantly recognised the native proteins (Fig. 4)
in the ELISA. In the Western blot analysis, the same result was
observed for all sera except those from mice immunised with P46
vaccine, which was not reactive (data not shown).
3.3. Real-time PCR
Total  RNA was  extracted from the spleens of immunised mice
and subjected to real-time PCR analysis. Both the recombinant sub-
unit and DNA vaccines showed less or equal IL1 expression than the
control (saline group and pcDNA3 group, respectively). On the other
hand, the bacterin-vaccinated group (positive control) showed IL1
expression higher than that of the control (saline group) (Fig. 5A).
The relative expression of TNF was lower in the mice immu-
nised with the bacterin and all recombinant vaccines except the
pcDNA3/P42 and pcDNA3/P95 vaccines relative to the control (Fig.
5B). This negative effect on the IL1 and TNF pro-inﬂammatory
cytokine response was more pronounced in the groups vaccinated
with P46, both as a recombinant subunit vaccine and a DNA vaccine.
Furthermore, the DNA-vaccinated groups showed higher IL1 and
TNF expression than the groups that received the recombinant
subunit vaccines.
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Fig. 3. Optical density (mean ± SD) obtained by sandwich ELISA using individual
sera  (100 g each well) from eight BALB/c mice immunised with the P37, P42, P46,
P95, pcDNA3/P37, pcDNA3/P42, pcDNA3/P46 and pcDNA3/P95 vaccines. The sera
were collected 84 days after inoculation. Anti-mouse IgG1 and IgG2a, supplied in
the IsoQuickTM kit (Sigma Aldrich), were used as secondary antibodies. The colori-
metric  reaction was  started by adding o-phenylenediamine dihydrochloride (Sigma
Aldrich) and hydrogen peroxide and was stopped with 2 M H2SO4. The optical den-
sities (492 nm)  of the recombinant subunit and DNA vaccines were subtracted from



















The pre-immune sera (day 0).
All recombinant subunit vaccines and the pcDNA3/P46 DNA vac-
ine induced more INF expression than the control (Fig. 5C). INF
s an important cytokine involved in cellular immune responses
Th1 type). As expected, pcDNA3/P46 elicited a stronger Th1
mmune response than the recombinant proteins. Although the
acterin vaccine also induced INF expression, the expression level
as statistically lower than that for all recombinant protein vac-
ines.
ig. 4. Indirect ELISA analysis using native proteins from M. hyopneumoniae strain
448 (1 g each well) as the antigens and individual serum (diluted 1:20) from
ice  immunised with the recombinant vaccines (P37, P42, P46, P95, pcDNA3/P37,
cDNA3/P42,  pcDNA3/P46, and pcDNA3/P95) collected 84 days after inoculation. An
nti-mouse IgG-peroxidase conjugate (diluted 1:4000) was used as the secondary
ntibody.  The colorimetric reaction was started by adding o-phenylenediamine
ihydrochloride (Sigma Aldrich) and hydrogen peroxide and was  stopped with 2 M
2SO4. The data show the optical density (492 nm)  after subtraction from the value
or the pre-immune serum (day 0). Treatments that differed from the negative con-
rol (saline for subunit vaccines and pcDNA3 for DNA vaccines) according to the
ukey test (P < 0.01) are marked with asterisks.
Fig. 5. Relative expression levels (mean RQ ± SD) of IL1 (A), TNF (B) and INF (C).
Spleens  from BALB/c mice immunised with P37, P42, P46 and P95, delivered as
recombinant subunit or DNA vaccines, were collected, and splenocytes were cul-
tured and stimulated with recombinant P37, P42, P46 or P95 proteins, respectively.
Total  RNA from these cultures was  used for real-time PCR analysis. The data show
the expression levels relative to those for the negative control (*saline group for sub-
unit vaccines and pcDNA3 vector for DNA vaccines). The values were normalised to
the level of the GAPDH housekeeping gene.
4. Discussion
Although commercial vaccines are widely used worldwide, they
provide only partial protection, highlighting the need for new vac-
cines with improved efﬁcacy [4,5]. In this study, four immunogenic
M. hyopneumoniae antigens, P37, P42, P46 and P95, were evaluated
as subunit and DNA vaccine candidates. The analysis of the anti-
body responses in mice vaccinated with both vaccine formulations
revealed that all subunit vaccines were able to induce speciﬁc IgG
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hat induced a humoral immune response. This is the ﬁrst report of
he immune response induced by pcDNA3/P46 delivered alone.
It  is not clear why the other DNA vaccine constructs failed to
licit serum IgG responses. The P37 protein was  recognised by
olyclonal antibodies in the immunoﬂuorescence assay, and P95
RNA was detected by RT-PCR in transfected Vero cells, indicat-
ng that these proteins were expressed. One possible explanation
ould be that the in vivo expression of these proteins was poor and
hat the quantities of antibodies induced by these proteins were
ot measurable. Furthermore, pcDNA3/P46 and the subunit vac-
ines for P42, P46 and P95 also induced antibodies able to recognise
ative proteins, as demonstrated in the ELISA (Fig. 4) and Western
lot analysis. These results indicate that the folding of these pro-
eins was most likely similar to that of the native proteins, with the
ppropriate epitopes exposed on the surface, unlike the proteins
roduced by pcDNA3/P37 and pcDNA3/P95. Thus, correct fold-
ng and/or other posttranslational modiﬁcations may  have allowed
cDNA3/P46 to generate antibodies when other antigens delivered
s DNA vaccines could not.
DNA vaccination has been demonstrated to induce both
umoral and cellular immune responses [8]. The immune system
odulation, the Th type and the IgG subclass distribution may  be
mportant for protection against enzootic pneumonia. Th1 cells can
nduce macrophages to destroy intracellular microorganisms more
fﬁciently and also activate B cells to produce strongly opsonising
ntibodies such as IgG2a and IgG2b in mice. In contrast, Th2 cells
nduce B cells to proliferate and produce antibodies such as IgG1
nd other types [21]. Therefore, we assayed the levels of the IgG1
nd IgG2a subclasses and of INF produced by immunised mice
ith the recombinant vaccines to assess the type of Th induction
f each vaccine. Protein vaccines are known to generally induce
redominately Th2 responses with weak or no Th1 responses. Sur-
risingly, all subunit recombinant vaccines elicited INF levels
igher than those induced by the negative control (Fig. 5C) and
y all DNA vaccines except pcDNA3/P46. The P42 and P95 vaccines
licited higher IgG2a levels than the other vaccines and induced a
ixed Th1/Th2-type immune response in mice, similar to what was
bserved when P42 was  delivered as a DNA vaccine [6]. Thus, both
accination strategies seem promising when using the P42 antigen.
eat shock proteins, such as P42, have been shown to be recog-
ised by multiple B-cell and T-cell clones [6] and have also been
sed as adjuvants to enhance cell-mediated immune responses in
NA vaccines [22]. Thus, the nature of the protein could be respon-
ible for the immune system modulation. However, it is important
o note that the induction of Th1 and Th2 immune responses by a
accine is species dependent and that the induction of antibodies in
ice against M.  hyopneumoniae is not correlated with protection.
herefore, further studies in pigs are necessary.
Interestingly, P46 use as a DNA vaccine generated more IgG1
nd IgG2a antibodies and also induced more INF gene expression
han when use as a subunit vaccine. It is important to note that the
umoral immune response of mice vaccinated with pcDNA3/P46
as not higher (P < 0.01) but was more consistent among animals
han the response to P46 delivered as a recombinant subunit vac-
ine. This result is in accordance with a recent study in which P46
licited a serum IgG response in mice intramuscularly immunised
ith a DNA vaccine cocktail comprising the antigens P36, P46, NrdF,
nd P97 or P97R1 [14]. However, the authors of that previous study
sed the entire sequence of P46, whereas we  omitted the ﬁrst
00 nucleotides to avoid the need to mutate two  additional TGA
odons. It appears that the omitted sequence is not necessary to
licit immune responses.The  evaluation of local and systemic immune responses induced
y the intramuscular injection of an M.  hyopneumoniae bacterin into
igs showed that the TNF- concentration in the BALF was higher in
on-vaccinated challenged pigs than in vaccinated challenged pigs (2012) 135– 140 139
[5].  The presence of IL1 and TNF in the BALF would thus appear
to be associated with the development of pneumonic lesions in M.
hyopneumoniae-infected pigs [23–25]. Therefore, reduction of the
inﬂammatory reaction caused by M.  hyopneumoniae is desirable.
In the present study, all evaluated vaccines reduced or maintained
the expression of IL1 and TNF relative to the negative control; the
P42 subunit vaccine and the P46 antigen delivered as a subunit or
DNA vaccine were particularly effective (Fig. 5). We hypothesised
that the reduction in expression of these cytokines was generated
by IL-10, an immunosuppressive cytokine, thus suggesting spe-
ciﬁc activation of regulatory T cell. However, the reduction in the
expression of these cytokines in non-challenged vaccinated mice
does not necessarily indicate that the expression levels of these
cytokines will also be reduced after the infection of vaccinated pigs
with M. hyopneumoniae. Thus, this result should be conﬁrmed in
studies using vaccinated pigs that are challenged with virulent M.
hyopneumoniae.
It may  be possible that the type of immune response induced
depends on the vaccine construct, the adjuvant used and the route
of immunisation in addition to the nature of the antigen itself.
Conceic¸ ão et al. [26] reported that mice immunised with a recom-
binant subunit vaccine containing P97R1 fused to the B subunit of
the heat-labile enterotoxin of E. coli induced Th1-biased immune
responses when given intranasally but not when given intramuscu-
larly (which induced Th2-biased responses). Chen et al. [7] showed
that Salmonella enteric serotype Typhimurium aroACS332 harbou-
ring a eukaryotic or prokaryotic expression vector encoding P97R1
or NrdF induced antigen-speciﬁc Th1-biased immune responses in
mice that were immunised orally. Mice immunised intranasally
with a replicative-defective recombinant adenovirus expressing
the C-terminal portion of M. hyopneumoniae P97 adhesin showed a
mixed Th1/Th2-type response against P97 [27]. The mycobacterial
ESAT-6 protein was  able to enhance the mouse IFN- response to
the M. hyopneumoniae P71 protein [28] and P71 DNA vaccines [29].
Therefore, it would be interesting to evaluate the differences in
the Th1 and Th2 immune responses induced by pcDNA3/P46 when
using other routes of vaccination.
It  is also important to note that the commercial vaccine
(Resp®Sure) induced antibodies in mice that were able to recognise
native proteins of M. hyopneumoniae but did not induce antibod-
ies able to recognise any of the recombinant proteins used in this
study. In addition, this commercial vaccine did not induce INF
gene expression. Similar results were reported by Marchioro et al.
[13] and Simionatto et al. [12] using a wide range of recombinant
proteins. The reason for the lack of recognition of the recombi-
nant proteins by antibodies induced by the commercial vaccine is
unknown. It is possible that the immunogenic proteins are present
at low concentrations in this vaccine formulation. Although we
have no conﬁrmation that immune response to these proteins
would induce any protection against infection, colonisation or dis-
ease in pigs after infection with M. hyopneumoniae, perhaps a
stronger protective effect could be obtained by adding, to the com-
mercial vaccine, immunogenic proteins such as those evaluated in
this study.
In  summary, we demonstrated that intramuscular immunisa-
tion with the pcDNA3/P46 vaccine delivered alone was able to
induce both Th1- and Th2-biased immune responses, with an
increase in the INF level but decreases in the levels of IL1 and
TNF, which are responsible for the lung lesions that occur during
M. hyopneumoniae infection. Additionally, P42 and P95, antigens
that had not been previously evaluated regarding the induction
of cellular immune responses, elicited high IgG2a and INF levels
when delivered as subunit vaccines. However, it is well known that
the immune responses of mice may  not always be extrapolated to
other species. In addition, immune responses are not only depend-
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sed. Therefore, further studies in pigs are required to evaluate the
bility of these vaccines to control enzootic pneumonia.
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